Long-acting injectable buprenorphine – ‘best practice’ opioid agonist therapy for Australian prisoners

2021 ◽  
pp. 103985622110590
Author(s):  
Scott Russ ◽  
Aboud Andrew ◽  
O’Gorman Thomas
Keyword(s):  
Best Practice ◽  
Substance Misuse ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy ◽  
Long Acting ◽  
Prison Populations

Objective To consider opioid agonist therapy in prisons. Conclusions Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as ‘best practice’ treatment in Australian prison populations.

950 Association between capacity for maternal opioid agonist therapy treatment and neonatal abstinence syndrome

2021 ◽  
Vol 224 (2) ◽  
pp. S589-S590
Author(s):  
Bronwyn S. Bedrick ◽  
Carly O'Donnell ◽  
Christine Marx ◽  
Hayley Friedman ◽  
Ebony B. Carter ◽  
...  
Keyword(s):  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy ◽  
Therapy Treatment

scholarly journals The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting

2017 ◽  
Vol 176 ◽  
pp. 133-138 ◽  
Author(s):  
Joseph K. Eibl ◽  
Graham Gauthier ◽  
David Pellegrini ◽  
Jeffery Daiter ◽  
Michael Varenbut ◽  
...  
Keyword(s):  
Clinical Setting ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy

scholarly journals Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy

2018 ◽  
Vol 32 (2) ◽  
pp. 347-370 ◽  
Author(s):  
Brianna L. Norton ◽  
Matthew J. Akiyama ◽  
Philippe J. Zamor ◽  
Alain H. Litwin
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy
Sign in / Sign up

Export Citation Format

Share Document